Trial Condition(s):

Clinical Pharmacology

BAY106-7197, Midazolam interaction study

Bayer Identifier:

15130

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2012-003803-36

Study Completed

Trial Purpose

The primary objective was to
• Investigate the influence of a single dose of BAY 1067197 on the pharmacokinetics of a single oral dose of midazolam in healthy male subjects
Secondary objective was to
• Assess safety and tolerability

Inclusion Criteria
Healthy young male subjects, 18 to 45 years of age, with body mass index between 18.0 and 29.9 kg/m2 inclusive were enrolled
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
12
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Neladenoson Bialanate (BAY1067197)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Bayer Pharma AG

Berlin, Germany, 13353

Status
Completed
 

Trial Design